Date: 2012-11-05
Type of information: Grant
Company: Creabilis (Luxembourg)
Investors: Biomedical Catalyst Fund (UK)
Amount: £1.42 million (€1.78 million)
Funding type: grant
Planned used: The award will be used by Creabilis in a £2.37m project to further develop CT327, a novel, first-in-class topical kinase inhibitor that is in clinical development to treat a number of dermatological diseases. Specifically, the funding will be used to support a Phase IIb clinical study to further evaluate the safety and efficacy of CT327 in patients with Atopic Dermatitis. CT327 has been developed using Creabilis’ Low Systemic Exposure (LSE) technology that creates ‘topical-by-design’ drugs optimised for high local and low systemic exposures. Previously, in an international Phase IIa study, CT327 was effective in treating all aspects of AD and has proven safe and well tolerated in a further five clinical studies.
Others: Creabilis SA, a European biotechnology company specialising in the development of treatments in dermatology, inflammation and pain has been granted a Biomedical Catalyst funding award, of £1.42m. The award was announced by Technology Strategy Board and is one of 32 projects awarded funding totalling £39 million. These are the first substantial awards made from the £ 180 million Biomedical Catalyst programme managed by the Technology Strategy Board and the Medical Research Council.
Therapeutic area: Dermatological diseases
